Hemophilia, an X-linked recessive genetic disorder triggered by deficiencies in clotting factors VIII or IX, predominantly affects males, manifesting as uncontrollable bleeding following spontaneous incidents or minor trauma, with severe cases posing life-threatening risks. While females commonly serve as carriers, they may also exhibit symptoms under specific circumstances.

Annually, April 17 marks "World Hemophilia Day," an international day established with the aim of increasing public awareness about hemophilia, fostering greater understanding and support for hemophilia patients and their families, and incentivizing research innovation to enhance the quality of life for those affected. The theme of the event this year is "Equitable access for all: recognizing all bleeding disorders".

In recent years, significant strides have been made in hemophilia research, with novel treatments such as gene therapy, long-acting clotting factor replacements, and small molecule drug development garnering considerable attention. Additionally, non-factor therapies, including antisense oligonucleotide drugs and antibody therapies, are showing promising potential in clinical trials, offering a more diverse range of treatment options for the future.

CUSABIO has always upheld the original intention of supporting scientific research and closely follows the latest developments in Hemophilia research. Therefore, we have carefully selected more than 20 popular targets closely related to Hemophilia research and provided a series of high-quality research reagents, including recombinant proteins, antibodies, ELISA kits, and more, to fully support your experimental needs and innovative research.